<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03391466</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-107</org_study_id>
    <nct_id>NCT03391466</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma</brief_title>
  <acronym>ZUMA-7</acronym>
  <official_title>A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kite, A Gilead Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the
      clinical outcome compared with standard of care second-line therapy in patients with
      relapsed/refractory DLBCL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 randomized, open-label, multicenter study evaluating the efficacy of
      axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed/refractory
      DLBCL. Adult subjects with relapsed/refractory DLBCL after first-line rituximab and
      anthracycline-based chemotherapy will be randomized in a 1:1 ratio to receive axicabtagene
      ciloleucel or standard of care second-line therapy.

      Standard of care will consist of a protocol-defined, platinum-based salvage combination
      chemotherapy regimen followed by high-dose therapy and autologous stem cell transplant in
      those who respond to salvage chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">January 15, 2035</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two arms, SOC and experimental treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>Axicabtagene Ciloleucel Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axicabtagene Ciloleucel</intervention_name>
    <description>Intervention Description: N/A.</description>
    <arm_group_label>Axicabtagene Ciloleucel Treatment</arm_group_label>
    <other_name>KTE-C19</other_name>
    <other_name>axi-cel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.</intervention_name>
    <description>Intervention Description: N/A.</description>
    <arm_group_label>Standard of Care Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Histologically proven DLBCL, including transformation from follicular lymphoma

          2. Relapsed or refractory disease after first-line chemoimmunotherapy

               -  Refractory disease is defined as no complete remission to first-line therapy;
                  subjects who are intolerant to first-line therapy are excluded.

                    -  Progressive disease (PD) as best response to first-line therapy

                    -  Stable disease (SD) as best response after at least 4 cycles of first-line
                       therapy

                    -  Partial response (PR) as best response after at least 6 cycles and
                       biopsy-proven residual disease or disease progression ≤ 12 months from
                       initiation of therapy

               -  Relapsed disease defined as complete remission to first-line therapy followed by
                  biopsy-proven relapse ≤ 12 months of initiating first-line therapy

          3. Subjects must have received adequate first-line therapy including at a minimum:

               -  Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20
                  negative, and

               -  An anthracycline containing chemotherapy regimen

          4. No known history or suspicion of central nervous system involvement by lymphoma

          5. ECOG performance status of 0 or 1

          6. Adequate bone marrow function as evidenced by:

               -  ANC ≥ 1000/uL

               -  Platelet ≥ 75,000/uL

               -  Absolute lymphocyte count ≥ 100/uL

          7. Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:

               -  Creatinine clearance (Cockcroft Gault) ≥ 60 mL/min

               -  Serum ALT/AST ≤ 2.5 ULN

               -  Total bilirubin ≤ 1.5 mg/dl

               -  Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as
                  determined by an ECHO, and no clinically significant ECG findings

               -  No clinically significant pleural effusion

               -  Baseline oxygen saturation &gt; 92% on room air

        Key Exclusion Criteria:

          1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg
             cervix, bladder, breast) unless disease free for at least 3 years

          2. Received more than one line of therapy for DLBCL

          3. History of autologous or allogeneic stem cell transplant

          4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
             requiring intravenous antimicrobials for management.

          5. Known history of infection with human immunodeficiency virus (HIV) or hepatitis B
             (HBsAg positive) or hepatitis C virus (anti-HCV positive). If there is a positive
             history of treated hepatitis B or hepatitis C, the viral load must be undetectable per
             quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.

          6. Subjects with detectable cerebrospinal fluid malignant cells or known brain
             metastases, or with a history of cerebrospinal fluid malignant cells or brain
             metastases.

          7. History or presence of non-malignant CNS disorder such as seizure disorder,
             cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune
             disease with CNS involvement

          8. Presence of any indwelling line or drain. Dedicated central venous access catheter
             such as a Port-a-Cath or Hickman catheter are permitted.

          9. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,
             New York Heart Association Class II or greater congestive heart failure, or other
             clinically significant cardiac diseases within 12 months of enrollment

         10. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of
             enrollment

         11. History of autoimmune disease, requiring systemic immunosuppression and/or systemic
             disease modifying agents within the last 2 years

         12. History of anti-CD19 or CAR-T therapy or history of prior randomization in ZUMA-7
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kite MD</last_name>
    <phone>+1-844-454-5483</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Winkle</last_name>
      <email>andrea.winkle@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Javier Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana Kristine Craig</last_name>
      <email>jkcraig@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>David Miklos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>12902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Scott</last_name>
      <email>Matthew.Scott@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Fred Locke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heelai Wardak</last_name>
      <email>hwardak1@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Riedell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Zehr</last_name>
      <email>pamela-zehr@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Umar Farooq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rocchio</last_name>
      <email>MichaelJ_Rocchio@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Caron Jacobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Folken</last_name>
      <email>mccstudyintake@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Johnston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phil Powell</last_name>
      <email>cpowell@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Armin Ghobadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Fritz</last_name>
      <email>fritzm2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Dorritie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Salfarlie</last_name>
      <email>kristina.salfarlie@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Ian Flinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Leonard-Martin</last_name>
      <email>thomas.leonard-martin@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Olalekan Oluwole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Atkins</last_name>
      <email>sadkins@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jason Westin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

